Predictability of the individual clinical outcome of extracorporeal shock wave therapy for cellulite

Kai-Uwe Schlaudraff, Maren C Kiessling, Nikolaus Bm Császár, Christoph Schmitz, Kai-Uwe Schlaudraff, Maren C Kiessling, Nikolaus Bm Császár, Christoph Schmitz

Abstract

Background: Extracorporeal shock wave therapy has been successfully introduced for the treatment of cellulite in recent years. However, it is still unknown whether the individual clinical outcome of cellulite treatment with extracorporeal shock wave therapy can be predicted by the patient's individual cellulite grade at baseline, individual patient age, body mass index (BMI), weight, and/or height.

Methods: Fourteen Caucasian females with cellulite were enrolled in a prospective, single-center, randomized, open-label Phase II study. The mean (± standard error of the mean) cellulite grade at baseline was 2.5±0.09 and mean BMI was 22.8±1.17. All patients were treated with radial extracorporeal shock waves using the Swiss DolorClast(®) device (Electro Medical Systems, S.A., Nyon, Switzerland). Patients were treated unilaterally with 2 weekly treatments for 4 weeks on a randomly selected side (left or right), totaling eight treatments on the selected side. Treatment was performed at 3.5-4.0 bar, with 15,000 impulses per session applied at 15 Hz. Impulses were homogeneously distributed over the posterior thigh and buttock area (resulting in 7,500 impulses per area). Treatment success was evaluated after the last treatment and 4 weeks later by clinical examination, photographic documentation, contact thermography, and patient satisfaction questionnaires.

Results: The mean cellulite grade improved from 2.5±0.09 at baseline to 1.57±0.18 after the last treatment (ie, mean δ-1 was 0.93 cellulite grades) and 1.68±0.16 at follow-up (ie, mean δ-2 was 0.82 cellulite grades). Compared with baseline, no patient's condition worsened, the treatment was well tolerated, and no unwanted side effects were observed. No statistically significant (ie, P<0.05) correlation was found between individual values for δ-1 and δ-2 and cellulite grade at baseline, BMI, weight, height, or age.

Conclusion: Radial shock wave therapy is a safe and effective treatment option for cellulite. The individual clinical outcome cannot be predicted by the patient's individual cellulite grade at baseline, BMI, weight, height, or age.

Keywords: AWT; EPAT; RSWT; acoustic wave therapy; extracorporeal pulse activation therapy; radial shock wave therapy.

Figures

Figure 1
Figure 1
Principles of radial shock wave technology. Notes: (A) DolorClast® device (Electro Medical Systems SA, Nyon, Switzerland) used in the present study. (B) Power+ hand piece of the Swiss DolorClast device with the 36 mm applicator used in the present study. Compressed air (1) is used to fire a projectile within a guiding tube (2) that strikes a 36 mm diameter metal applicator (3) placed on the skin. The projectile generates stress waves in the applicator that transmit pressure waves noninvasively into tissue. (C) Pressure wave generated with the Swiss DolorClast device, measured at a distance of 1 mm from the applicator (Power+ hand piece, 36 mm applicator, device operated at 4 bar air pressure and 15 Hz impulse frequency as used in the present study). After a delay of approximately 2 μseconds, the pressure wave shows an increase in (positive) pressure (i), followed by a decrease in pressure (ii) with reaching zero at approximately 8 μseconds, a subsequent period of negative pressure (iii) interrupted by a period of positive pressure (iv). (DO) Cavitation bubbles (black dots) in degassed water generated during the phase of negative pressure of radial shock waves generated with the Power+ hand piece and the 36 mm applicator of the Swiss DolorClast device operated at 4 bar air pressure at 15 Hz (DI) as used in the present study or at 1 Hz (JO) either at the center of the applicator (D, E, F, J, K and L) or the edge of the applicator (G, H, I, M, N and O). Note that the arrows point to the center of the applicator. Maximum cavitation is shown in (E, H, K and N). The images shown in (D, G, J and M) were taken approximately 1.5 mseconds before the cavitation maximum, and images shown in (F, I, L and O) were taken approximately 1.5 mseconds after the cavitation maximum. Cavitation lasted for approximately one mseconds. The pictures were taken with a high-speed CCD camera (Photron Ultima APX; Photron, Tokyo, Japan) with a framing rate of 300,000 frames per second and an exposure time of 1/2,700,000 seconds. The scale bar in (O) represents 10 mm. Note that the cavitation field (and thus the pressure field below the applicator) is broader when generating radial shock waves at 15 Hz (DI) than at 1 Hz (JO). This phenomenon is observed for many radial shock wave devices (Császár et al, submitted for publication).
Figure 2
Figure 2
Radial shock wave therapy for cellulite. Notes: (A) Application of coupling gel. (B) Treatment with the Power+ hand piece of the Swiss DolorClast® device (Electro Medical Systems, Nyon, Switzerland).
Figure 3
Figure 3
Treatment of two patients (1, 2) with cellulite using radial extracorporeal shock wave therapy. Notes: (A1 and A2) Clinical picture at baseline. (B1 and B2) Contact thermography at baseline. (C1 and C2) Clinical picture 4 weeks after the last treatment (follow-up). (D1 and D2) Contact thermography at follow-up. (A1D1) A 29-year-old female (body mass index 32.9, weight 84.3 kg, height 160 cm). Radial extracorporeal shock wave therapy performed on the left side improved the cellulite from grade 3 at baseline to grade 1–2 at follow-up (ie, δ-2 was 1.5). Despite this objectively substantial treatment success, the patient’s satisfaction was only 5 on a scale ranging from 0 (maximum dissatisfaction) to 10 (maximum satisfaction). (A2D2) A 51-year-old female (body mass index 20.8; weight 53.3 kg; height 160 cm). Radial extracorporeal shock wave therapy performed on the right side improved the cellulite from grade 2–3 at baseline to grade 1–1.5 at follow-up (ie, δ-2 was 1.25). This patient was very satisfied with the treatment (9 on a scale ranging from 0 to 10). Patient consent was obtained to publish the above images.
Figure 4
Figure 4
Clinical outcome of radial extracorporeal shock wave therapy for cellulite as a function of the patients’ initial cellulite grade at baseline (A and B), BMI (C and D), weight (E and F), height (G and H) and age (I and J) (calculated as individual difference in cellulite grades either between baseline and after the last treatment [δ-1] or between baseline and at follow-up [δ-2], respectively; the higher δ-1 and δ-2, the better the treatment success). Notes: Each dot represents an individual patient; overlapping data are indicated. The Spearman’s nonparametric rank correlation coefficients (r) and the corresponding P-values are provided in red on top of each panel. Abbreviation: BMI, body mass index.
Figure 5
Figure 5
Clinical outcome of radial extracorporeal shock wave therapy for cellulite as a function of the patients’ pain during the treatment (A and B), the patients’ feeling of comfort during treatment (C and D), and the patients’ satisfaction with treatment (E and F) (calculated as individual difference in cellulite grades either between baseline and after the last treatment [δ-1] or between baseline and at follow-up [δ-2], respectively; the higher δ-1 and δ-2, the better the treatment success). Notes: Each dot represents an individual patient; overlapping data are indicated. Pain was assessed using a visual analog scale ranging from 0 (no pain) to 10 (maximum pain). The feeling of comfort was assessed using a scale ranging from 0 (maximum discomfort) to 10 (maximum comfort), and patients’ satisfaction using a scale ranging from 0 (maximum dissatisfaction) to 10 (maximum satisfaction). The Spearman’s nonparametric rank correlation coefficients (r) and the corresponding P-values are provided in red on top of each panel.
Figure 6
Figure 6
Relationship between the individual difference in cellulite grades between baseline and after the last treatment (δ-1) and between baseline and at follow-up (δ-2) after radial extracorporeal shock wave therapy for cellulite (the higher δ-1 and δ-2, the better the treatment success). Notes: Each dot represents an individual patient; overlapping data are indicated. Red, black, and green dots/asterisks indicate patients whose cellulite grade worsened, remained unchanged, or improved, respectively, during the follow-up period compared with the situation after the last treatment. The Spearman’s nonparametric rank correlation coefficient (r) and the corresponding P-value are provided in red on top of the panel.

References

    1. Rossi AB, Vergnanini AL. Cellulite: a review. J Eur Acad Dermatol Venereol. 2000;14:251–262.
    1. Avram MM. Cellulite: a review of its physiology and treatment. J Cosmet Laser Ther. 2004;6:181–185.
    1. Khan MH, Victor F, Rao B, Sadick NS. Treatment of cellulite: Part I. Pathophysiology. J Am Acad Dermatol. 2010;62:361–370.
    1. de la Casa Almeida M, Suarez Serrano C, Rebollo Roldán J, Jiménez Rejano JJ. Cellulite’s aetiology: a review. J Eur Acad Dermatol Venereol. 2013;27:273–278.
    1. Emanuele E, Bertona M, Geroldi D. A multilocus candidate approach identifies ACE and HIF1A as susceptibility genes for cellulite. J Eur Acad Dermatol Venereol. 2010;24:930–935.
    1. Stavroulaki A, Pramantiotis G. Cellulite, smoking and angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism. J Eur Acad Dermatol Venereol. 2011;25:1116–1117.
    1. Nürnberger F, Müller G. So-called cellulite: an invented disease. J Dermatol Surg Oncol. 1978;4:221–229.
    1. Rosenbaum M, Prieto V, Hellmer J, et al. An exploratory investigation of the morphology and biochemistry of cellulite. Plast Reconstr Surg. 1998;101:1934–1939.
    1. Smalls LK, Lee CY, Whitestone J, Kitzmiller WJ, Wickett RR, Visscher MO. Quantitative model of cellulite: three-dimensional skin surface topography, biophysical characterization, and relationship to human perception. J Cosmet Sci. 2005;56:105–120.
    1. Lotti T, Ghersetich I, Grappone C, Dini G. Proteoglycans in so-called cellulite. Int J Dermatol. 1990;29:272–274.
    1. Terranova F, Berardesca E, Maibach H. Cellulite: nature and aetiopathogenesis. Int J Cosmet Sci. 2006;28:157–167.
    1. Avram MM, Avram AS, James WD. Subcutaneous fat in normal and diseased states: 1. Introduction. J Am Acad Dermatol. 2005;53:663–670.
    1. Khan MH, Victor F, Rao B, Sadick NS. Treatment of cellulite: Part II. Advances and controversies. J Am Acad Dermatol. 2010;62:373–384.
    1. Rossi AM, Katz BE. A modern approach to the treatment of cellulite. Dermatol Clin. 2014;32:51–59.
    1. Sattler G, Pohl U, Raegener K. [Pilot study acoustic wave therapy (AWT) for cellulite] Aesthet Dermatol. 2008;2:17–25. German.
    1. Knobloch K, Joest B, Krämer R, Vogt PM. Cellulite and focused extracorporeal shockwave therapy for non-invasive body contouring: a randomized trial. Dermatol Ther. 2013;3:143–155.
    1. Russe-Wilflingseder K, Russe E, Vester JC, Haller G, Novak P, Krotz A. Placebo controlled, prospectively randomized, double-blinded study for the investigation of the effectiveness and safety of the acoustic wave therapy (AWT®) for cellulite treatment. J Cosmet Laser Ther. 2013;15:155–162.
    1. Braun MT, Daser A, Wroblewska KK. [Effects of shock wave therapy on pathological changes in subcutaneous adipose tissue. A pilot study] Aesthet Dermatol. 2005;4:11–17. German.
    1. Angehrn F, Kuhn C, Voss A. Can cellulite be treated with low-energy extracorporeal shock wave therapy? Clin Interv Aging. 2007;2:623–630.
    1. Christ C, Brenke R, Sattler G, Gabriel S, Siems W, Daser A. Incerase of skin elasticity and revitalization of the dermis in cellulite and connective tissue weakness by extracorporeal acoustic wave therapy. Aesthet Dermatol. 2008a;1:6–14. German.
    1. Christ C, Brenke R, Sattler S, Siems W, Novak P, Daser A. Improvement in skin elasticity and dermal revitalization in the treatment of cellulite and connective tissue weakness by means of extracorporeal pulse activation therapy: EPAT. Aesthet Surg J. 2008;28:538–544.
    1. Adatto M, Adatto-Neilson R, Servant JJ, Vester J, Novak P, Krotz A. Controlled, randomized study evaluating the effects of treating cellulite with AWT/EPAT. J Cosmet Laser Ther. 2010;12:176–182.
    1. Kuhn C, Angehrn F, Sonnabend O, Voss A. Impact of extracorporeal shock waves on the human skin with cellulite: a case study of an unique instance. Clin Interv Aging. 2008;3:201–210.
    1. Ueberle F. Shock wave technology. In: Siebert W, Buch M, editors. Extracorporeal Shock Waves in Orthopaedics. 1st ed. Berlin, Germany: Springer; 1998. pp. 59–87.
    1. Ueberle F. Einsatz von Stoßwellen in der Medizin [Application of shock waves in medicine] In: Kramme R, editor. Medizintechnik. 1st ed. Berlin, Germany: Springer; 2007. pp. 483–513. German.
    1. Schleberger R, Delius M, Dahmen GP, et al. Orthopaedic extracorporeal shock wave therapy (ESWT). Method analysis and suggestion of a prospective study design – consensus report. In: Chaussy C, Eisenberger F, Jocham D, Wilbert D, editors. High Energy Shock Waves in Medicine. 1st ed. Stuttgart, Germany: Thieme; 1997.
    1. Ogden JA, Tóth-Kischkat A, Schultheiss R. Principles of shock wave therapy. Clin Orthop Relat Res. 2001;387:8–17.
    1. Rompe JD, Furia J, Weil L, Maffulli N. Shock wave therapy for chronic plantar fasciopathy. Br Med Bull. 2007;81–82:183–208.
    1. Schmitz C, Császár NB, Rompe JD, Chaves H, Furia JP. Treatment of chronic plantar fasciopathy with extracorporeal shock waves (review) J Orthop Surg Res. 2013;8:31.
    1. Rassweiler JJ, Knoll T, Köhrmann KU, et al. Shock wave technology and application: an update. Eur Urol. 2011;59:784–796.
    1. Gerdesmeyer L, Weil LS. Extracorporeal Shock Wave Therapy. Technologies Basics Clinical Results. 1st ed. Brooklandville, MD, USA: Data Trace Media; 2007.
    1. Császár NB, Schmitz C. Extracorporeal shock wave therapy in musculoskeletal disorders. J Orthop Surg Res. 2013;8:22.
    1. Gerdesmeyer L, Maier M, Haake M, Schmitz C. [Physical-technical principles of extracorporeal shockwave therapy (ESWT)] Orthopade. 2002;31:610–617. German.
    1. Trademark Electronic Search System (TESS) of the United States Patent and Trademark Office Available from: . Serial Number 79065686; Registration Number 3712310.
    1. Trademark Electronic Search System (TESS) of the United States Patent and Trademark Office Available from: . Serial Number 77249758; Registration Number 3593746.
    1. DePace R. Pulsed-activated therapy. J Foot Ankle Surg. 2011;50:783.
    1. Saxena A, Ramdath S, Jr, O’Halloran P, Gerdesmeyer L, Gollwitzer H. Pulsed-activated therapy. J Foot Ankle Surg. 2011;50:783–784.
    1. Concept Clinic Extracorporeal Shock Wave Treatment for Cellulite. [Accessed May 11, 2014]. Available from: . NLM identifier: NCT01974115.
    1. Shaffer JP. Multiple hypothesis testing. Annu Rev Psychol. 1965;46:561–584.
    1. Cleveland RO, Chitnis PV, McClure SR. Acoustic field of a ballistic shock wave therapy device. Ultrasound Med Biol. 2007;33:1327–1335.
    1. Perez C, Chen H, Matula TJ, Karzova M, Khokhlova VA. Acoustic field characterization of the Duolith: measurements and modeling of a clinical shock wave therapy device. J Acoust Soc Am. 2013;134:1663–1674.
    1. Saxena A, Ramdath S, Jr, O’Halloran P, Gerdesmeyer L, Gollwitzer H. Extra-corporeal pulsed-activated therapy (“EPAT” sound wave) for Achilles tendinopathy: a prospective study. J Foot Ankle Surg. 2011;50:315–319.
    1. European Medicines Agency Guideline on missing data in confirmatory clinical trials. 2010. [Accessed May 11, 2014]. Available from: .
    1. Ferraro GA, De Francesco F, Cataldo C, Rossano F, Nicoletti G, D’Andrea F. Synergistic effects of cryolipolysis and shock waves for noninvasive body contouring. Aesthetic Plast Surg. 2012;36:666–679.
    1. Maier M, Averbeck B, Milz S, Refior HJ, Schmitz C. Substance P and prostaglandin E2 release after shock wave application to the rabbit femur. Clin Orthop Relat Res. 2003;406:237–245.
    1. Klonschinski T, Ament SJ, Schlereth T, Rompe JD, Birklein F. Application of local anesthesia inhibits effects of low-energy extracorporeal shock wave treatment (ESWT) on nociceptors. Pain Med. 2011;12:1532–1537.
    1. Snijdelaar DG, Dirksen R, Slappendel R, Crul BJ. Substance P. Eur J Pain. 2000;4:121–135.
    1. Burks TF, Buck SH, Miller MS. Mechanisms of depletion of substance P by capsaicin. Fed Proc. 1985;44:2531–2534.
    1. Quatresooz P, Piérard GE. Immunohistochemical clues at aging of the skin microvascular unit. J Cutan Pathol. 2009;36:39–43.
    1. Mlosek RK, WoŸniak W, Malinowska S, Lewandowski M, Nowicki A. The effectiveness of anticellulite treatment using tripolar radiofrequency monitored by classic and high-frequency ultrasound. J Eur Acad Dermatol Venereol. 2012;26:696–703.
    1. Nootheti PK, Magpantay A, Yosowitz G, Calderon S, Goldman MP. A single center, randomized, comparative, prospective clinical study to determine the efficacy of the VelaSmooth system versus the Triactive system for the treatment of cellulite. Lasers Surg Med. 2006;38:908–912.
    1. Goldberg DJ, Fazeli A, Berlin AL. Clinical, laboratory, and MRI analysis of cellulite treatment with a unipolar radiofrequency device. Dermatol Surg. 2008;34:204–209.
    1. Sadick NS, Mulholland RS. A prospective clinical study to evaluate the efficacy and safety of cellulite treatment using the combination of optical and RF energies for subcutaneous tissue heating. J Cosmet Laser Ther. 2004;6:187–190.
    1. Sadick N, Magro C. A study evaluating the safety and efficacy of the VelaSmooth system in the treatment of cellulite. J Cosmet Laser Ther. 2007;9:15–20.
    1. Prado A, Andrades P, Danilla S, Leniz P, Castillo P, Gaete F. A prospective, randomized, double-blind, controlled clinical trial comparing laser-assisted lipoplasty with suction-assisted lipoplasty. Plast Reconstr Surg. 2006;118:1032–1045.
    1. Nagy MW, Vanek PF., Jr A multicenter, prospective, randomized, single-blind, controlled clinical trial comparing VASER-assisted lipoplasty and suction-assisted lipoplasty. Plast Reconstr Surg. 2012;129(4):681e–689e.
    1. Katz B, McBean J, Cheung JS. The new laser liposuction for men. Dermatol Ther. 2007;20:448–451.
    1. Kim KH, Geronemus RG. Laser lipolysis using a novel 1064 nm Nd:YAG laser. Dermatol Surg. 2006;32:241–248.
    1. Lis-Balchin M. Parallel placebo-controlled clinical study of a mixture of herbs sold as a remedy for cellulite. Phytother Res. 1999;13:627–629.
    1. Kligman AM, Pagnoni A, Stoudemayer T. Topical retinol improves cellulite. J Dermatol Treat. 1999;10:119–125.
    1. Sasaki GH, Oberg K, Tucker B, Gaston M. The effectiveness and safety of topical PhotoActif phosphatidylcholine-based anti-cellulite gel and LED (red and near-infrared) light on Grade II–III thigh cellulite: a randomized, double-blinded study. J Cosmet Laser Ther. 2007;9:87–96.
    1. Moreno-Moraga J, Valero-Altés T, Riquelme AM, Isarria-Marcosy MI, de la Torre JR. Body contouring by non-invasive transdermal focused ultrasound. Lasers Surg Med. 2007;39:315–323.
    1. Collis N, Elliot LA, Sharpe C, Sharpe DT. Cellulite treatment: a myth or reality: a prospective randomized, controlled trial of two therapies, endermologie and aminophylline cream. Plast Reconstr Surg. 1999;104:1110–1114.
    1. Chang P, Wiseman J, Jacoby T, Salisbury AV, Ersek RA. Noninvasive mechanical body contouring: (Endermologie) a one-year clinical outcome study update. Aesthetic Plast Surg. 1998;22:145–153.
    1. Smalls LK, Hicks M, Passeretti D, et al. Effect of weight loss on cellulite: gynoid lypodystrophy. Plast Reconstr Surg. 2006;118:510–516.
    1. Mauriège P, Imbeault P, Langin D, et al. Regional and gender variations in adipose tissue lipolysis in response to weight loss. J Lipid Res. 1999;40:1559–1571.
    1. Hexsel DM, Serra M, Mazzuco R, Dal’Forno T, Zechmeister D. Phosphotidylcholine in the treatment of localized fat. J Drugs Dermatol. 2003;2:511–518.
    1. Rotunda AM, Suzuki H, Moy RL, Kolodney MS. Detergent effects of sodium deoxycholate are a major feature of an injectable phosphatidylcholine formulation used for localized fat dissolution. Dermatol Surg. 2004;30:1001–1008.
    1. Brandi C, D’Aniello C, Grimaldi L, et al. Carbon dioxide therapy in the treatment of localized adiposities: clinical study and histopathological correlations. Aesthetic Plast Surg. 2001;25:170–174.
    1. Brandi C, D’Aniello C, Grimaldi L, Caiazzo E, Stanghellini E. Carbon dioxide therapy: effects on skin irregularity and its use as a complement to liposuction. Aesthetic Plast Surg. 2004;28:222–225.
    1. Coleman WP. Liposuction. In: Coleman WP, Hanke CW, Alt TH, editors. Cosmetic Surgery of the Skin: Principles and Practice. 1st ed. Philadelphia, PA, USA: BC Decker; 1991.
    1. Môle B. La lipolyse chimique sous-cutanee par la phosphatidylcholine: une experience de cinq annees [A five years experience of subcutaneous chemical lipolysis with phosphatidylcholine injections] Ann Chir Plast Esthet. 2011;56:112–119. French.
    1. Manstein D, Laubach H, Watanabe K, Farinelli W, Zurakowski D, Anderson RR. Selective cryolysis: a novel method of non-invasive fat removal. Lasers Surg Med. 2008;40:595–604.
    1. Hexsel DM, Mazzuco R. Subcision: a treatment for cellulite. Int J Dermatol. 2000;39:539–544.
    1. Canadian Task Force on the Periodic Health Examination The periodic health examination. Can Med Assoc J. 1979;121:1193–1254.
    1. Siems W, Grune T, Voss P, Brenke R. Anti-fibrosclerotic effects of shock wave therapy in lipedema and cellulite. Biofactors. 2005;24:275–282.

Source: PubMed

3
Sottoscrivi